Narwhal Capital Management Sells 1,302 Shares of Johnson & Johnson (NYSE:JNJ)

Narwhal Capital Management lessened its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.5% during the third quarter, Holdings Channel reports. The fund owned 84,584 shares of the company’s stock after selling 1,302 shares during the quarter. Johnson & Johnson comprises 2.0% of Narwhal Capital Management’s investment portfolio, making the stock its 11th largest position. Narwhal Capital Management’s holdings in Johnson & Johnson were worth $13,818,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares in the last quarter. FMR LLC grew its holdings in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares during the period. GQG Partners LLC grew its position in shares of Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after acquiring an additional 2,547,378 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Johnson & Johnson by 52.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after buying an additional 2,093,392 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after buying an additional 1,805,632 shares in the last quarter. 67.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on JNJ shares. Citigroup increased their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target for the company. SVB Leerink decreased their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday. Barclays initiated coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Finally, Morgan Stanley cut their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.75.

Insider Transactions at Johnson & Johnson

In other news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider William Hait sold 15,000 shares of the company’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the transaction, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 277,886 shares of company stock worth $48,550,549. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 0.5 %

JNJ stock opened at $168.74 on Friday. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The business has a fifty day simple moving average of $176.14 and a 200-day simple moving average of $171.25. The company has a market cap of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.28 and a beta of 0.56. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.